1. Home
  2. DT vs PRAX Comparison

DT vs PRAX Comparison

Compare DT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynatrace Inc.

DT

Dynatrace Inc.

HOLD

Current Price

$33.84

Market Cap

10.7B

Sector

Technology

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$322.00

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DT
PRAX
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
9.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
DT
PRAX
Price
$33.84
$322.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
24
15
Target Price
$52.83
$572.13
AVG Volume (30 Days)
5.8M
350.2K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
205.77
N/A
EPS
0.48
N/A
Revenue
$1,698,683,000.00
N/A
Revenue This Year
$21.74
N/A
Revenue Next Year
$14.85
$6,395.88
P/E Ratio
$76.63
N/A
Revenue Growth
18.75
N/A
52 Week Low
$33.24
$28.12
52 Week High
$57.55
$354.87

Technical Indicators

Market Signals
Indicator
DT
PRAX
Relative Strength Index (RSI) 34.63 53.40
Support Level $33.24 $282.49
Resistance Level $39.66 $327.65
Average True Range (ATR) 1.39 17.80
MACD -0.26 2.46
Stochastic Oscillator 1.52 66.71

Price Performance

Historical Comparison
DT
PRAX

About DT Dynatrace Inc.

Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: